Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
4 evidence topics · 6 sources
Summary
UDCA is first-line treatment, while fibrates remain off-label alternatives and are discouraged in decompensated liver disease. The seladelpar prescribing information states that improved survival or prevention of liver decompensation has not been demonstrated. Obeticholic acid is no longer a current U.S. option: FDA withdrawal of approval took effect on November 24, 2025. Symptom management also remains incomplete; in TARGET-PBC, 33% of participants reporting clinically significant pruritus had never received treatment for it.